分子細胞遺伝学市場：製品別（キット、試薬、プローブ、機器、ソフトウェア、サービス）、手法別（FISH、CISH、比較ゲノムハイブリダイゼーション（アレイベース、標準））、用途別（癌、遺伝性疾患）-2028年までの世界予測

Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization (Array-based, Standard)), Application (Cancer, Genetics Disorders) - Global Forecast to 2028

分子細胞遺伝学市場は、2023年には推定31億米ドルと評価され、予測期間中のCAGRは9.9%で、2028年には49億米ドルに達すると予測されている。癌や遺伝性疾患のような慢性疾患の罹患率の増加は、より早い段階での疾... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2024年1月24日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	235	184	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

分子細胞遺伝学市場は、2023年には推定31億米ドルと評価され、予測期間中のCAGRは9.9%で、2028年には49億米ドルに達すると予測されている。癌や遺伝性疾患のような慢性疾患の罹患率の増加は、より早い段階での疾患の診断と疾患の核心的な原因の診断の普及率の上昇につながっている。これらの患者を管理するには、緊急かつタイムリーな治療が必要である。研究および診断手順の全体的な増加は、疾患の正確な診断を確実にするために分子細胞遺伝学の採用増加につながっている。これが市場全体の成長を牽引している。
"予測期間中、分子細胞遺伝学市場において、製品別ではキット＆試薬セグメントが最も高い成長率を占めた。"
分子細胞遺伝学市場は、製品ベースでキット＆試薬、機器、消耗品、ソフトウェア＆サービスに二分される。分子細胞遺伝学市場のキット＆試薬セグメントは、癌などの疾患の発生率の増加や個別化医療への注目の高まりが主な要因となって、大幅な成長を遂げている。
"予測期間中、分子細胞遺伝学市場の技術別成長率は比較ゲノムハイブリダイゼーションセグメントが最も高かった"
分子細胞遺伝学市場は、技術別に比較ゲノムハイブリダイゼーション、蛍光in-situハイブリダイゼーション、発色in-situハイブリダイゼーション、その他の技術に二分される。分子細胞遺伝学市場における比較ゲノムハイブリダイゼーション分野は、臨床病理学および研究における分子細胞遺伝学の浸透の増加により、大幅な成長を遂げている。
"予測期間中、分子細胞遺伝学市場のアプリケーション別では、癌分野が最も高い成長率を占めた。"
世界の分子細胞遺伝学市場は、遺伝性疾患、がん、個別化医療、その他の用途に二分される。現在、分子細胞遺伝学市場の中で最も高い成長率を示しているのは癌分野である。老年人口の増加と遺伝的変化による癌の発生率の上昇がこのセグメントの成長を促進する主な要因である。
"臨床＆研究ラボセグメントが最も高いCAGRを占めた"
エンドユーザーに基づき、分子細胞遺伝学市場は臨床＆研究ラボ、学術研究機関、製薬＆バイオテクノロジー企業、その他のエンドユーザーに区分される。2022年には、臨床＆研究ラボ部門が最も高い成長率を占めた。これは、疾患診断のための先進的な細胞遺伝学製品に対する需要の増加に起因している。
「アジア太平洋：最も急成長している地域の分子細胞遺伝学市場"
世界の分子細胞遺伝学市場は、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカに区分される。アジア太平洋地域は予測期間中に最も高いCAGRを記録すると予測されている。この地域の成長は主に中国と日本に集中すると予想される。高齢者人口の増加、がん罹患率の上昇、医療費の増加、一人当たり所得の増加、先端技術に対する需要の高まり、APAC諸国における民間医療部門の拡大、急速に発展する市場の存在などの要因が、この地域における市場成長の舵取り役となっている。
分子細胞遺伝学市場の主要参入企業のプロファイルの内訳：

- 企業タイプ別：企業タイプ別：Tier 1 - 40%、Tier 2 - 30%、Tier 3 - 30
- 役職別Cレベル：27％、Dレベル：18％、その他：55
- 地域別北米：51％、欧州：21％、アジア太平洋地域：18％、中南米：6％、中東・アフリカ：4
同市場の主要プレーヤーは、Thermo Fisher Scientific Inc.（米国）、Illumina Inc.（米国）、Danaher Corporation（米国）、F. Hoffmann-La Roche Ltd. （スイス）、Revvity（スイス）である。(スイス）、Revvity（米国）、Abbott Laboratories（米国）、Agilent Technologies, Inc.（米国）、Pacific Biosciences（米国）、Bio-Rad Laboratories, Inc.（米国）、Bio-Techne Corporation（米国）、GeneDx（米国）、Oncocyte Corporation（米国）、BioView（イスラエル）、Oxford Gene Technology IP, Limited.(英国）、Applied Spectral Imaging社（米国）、Cyto-Test社（米国）、KromaTiD社（米国）、Genial Genetic Solutions社（英国）、Cytognom社（英国）、GeneDx社（米国）、Oncocyte社（米国）、BioView社（イスラエル）、Oxford Gene Technology IP, Limited.(英国）、Cytognomix社（カナダ）、MetaSystems社（ドイツ）、SciGene社（米国）、Biomodal社（英国）、Biocare Medical社（米国）、BioDot社（米国）、OncoDNA社（ベルギー）。
調査範囲
この調査レポートは、分子細胞遺伝学市場を製品別（キット＆試薬、機器、消耗品、ソフトウェア＆サービス）、技術別（比較ゲノムハイブリダイゼーション、蛍光in-situハイブリダイゼーション、発色in-situハイブリダイゼーション、その他の技術）、用途別（遺伝性疾患、がん、個別化医療、その他の用途）、エンドユーザー別（臨床＆研究ラボ、学術研究機関、製薬＆バイオテクノロジー企業、その他のエンドユーザー）、地域別（北米、欧州、アジア太平洋地域、中南米、中東＆アフリカ）に分類しています。本レポートでは、分子細胞遺伝学市場の成長に影響を与える推進要因、阻害要因、機会、課題などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューションとサービス、主要戦略、買収、契約に関する洞察を提供しています。分子細胞遺伝学市場に関連する新製品の発表と最近の開発。分子細胞遺伝学市場のエコシステムにおける今後の新興企業の競合分析もカバーしています。
本レポートを購入する理由
本レポートは、分子細胞遺伝学市場全体およびサブセグメントの収益数の最も近い近似値に関する情報を提供することで、本市場の市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供します。
本レポートは、以下のポイントに関する洞察を提供しています：
- 分子細胞遺伝学市場の成長に影響を与える主な促進要因（がんおよび遺伝性疾患の発生率の増加、標的がん治療への注目の高まり、高齢化人口の急増とそれに伴う慢性疾患の有病率の増加、臨床病理学的検査における分子細胞遺伝学の浸透の高まり）、阻害要因（先端機器の高コスト、不利な償還シナリオ）、機会（アジアにおける未開拓の新興市場）、課題（FISHからアレイベース技術への移行）の分析。
- 製品開発／イノベーション：分子細胞遺伝学市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域の分子細胞遺伝学市場を分析しています。
- 市場の多様化：分子細胞遺伝学市場における新製品、未開拓地域、最近の開発、投資に関する詳細な情報
- 競合評価：F. Hoffmann-La Roche Ltd.（スイス）、Danaher Corporation（スイス）、Danaher Corporation（スイス）など主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。(スイス）、Danaher Corporation（米国）、Agilent Technologies, Inc.（米国）、Abbott Laboratories（米国）、Thermo Fisher Scientific Inc.

ページTOPに戻る

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 28
1.3 STUDY SCOPE 29
1.3.1 MARKET SEGMENTATION 29
1.3.2 GEOGRAPHIC SCOPE 30
1.3.3 YEARS CONSIDERED 30
1.4 CURRENCY 31
1.5 LIMITATIONS 31
1.6 STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.2 RESEARCH APPROACH 33
FIGURE 1 MOLECULAR CYTOGENETICS MARKET: RESEARCH DESIGN METHODOLOGY 33
2.2.1 SECONDARY DATA 34
2.2.1.1 Key data from secondary sources 34
2.2.2 PRIMARY DATA 35
2.2.2.1 Primary sources 36
2.2.2.2 Key data from primary sources 36
2.2.2.3 Key industry insights 37
2.2.2.4 Breakdown of primary interviews 37
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 38
2.3 MARKET SIZE ESTIMATION 38
2.3.1 BOTTOM-UP APPROACH 39
2.3.1.1 Approach 1: Company revenue estimation approach 39
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 39
2.3.1.2 Approach 2: Presentations of companies and primary interviews 39
2.3.1.3 Growth forecast 40
2.3.1.4 CAGR projections 40
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40
2.3.2 TOP-DOWN APPROACH 41
FIGURE 6 MOLECULAR CYTOGENETICS MARKET: TOP-DOWN APPROACH 41
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 42
FIGURE 7 DATA TRIANGULATION METHODOLOGY 42
2.5 MARKET SHARE ANALYSIS 43
2.6 STUDY ASSUMPTIONS 43
2.7 RISK ASSESSMENT 44
2.8 GROWTH RATE ASSUMPTIONS 44
2.9 RECESSION IMPACT 44
3 EXECUTIVE SUMMARY 47
FIGURE 8 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 9 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 10 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 48
FIGURE 11 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 MOLECULAR CYTOGENETICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 50
4 PREMIUM INSIGHTS 51
4.1 MOLECULAR CYTOGENETICS MARKET OVERVIEW 51
FIGURE 13 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET 51
4.2 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 52
FIGURE 14 KITS & REAGENTS TO CONTINUE TO DOMINATE MARKET IN 2028 52
4.3 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028 52
FIGURE 15 COMPARATIVE GENOMIC HYBRIDIZATION TO CONTINUE TO DOMINATE MOLECULAR CYTOGENETICS MARKET IN 2028 52
4.4 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023 VS. 2028 53
FIGURE 16 CANCER WILL CONTINUE TO DOMINATE MOLECULAR CYTOGENETICS MARKET IN 2028 53
4.5 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023 VS. 2028 53
FIGURE 17 CLINICAL & RESEARCH LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 53
4.6 MOLECULAR CYTOGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR CYTOGENETICS MARKET DURING FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
FIGURE 19 MOLECULAR CYTOGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
5.2.1 MARKET DRIVERS 56
5.2.1.1 Increasing incidence of cancer and genetic disorders 56
TABLE 1 PREVALENCE OF GENETIC DISORDERS (2021) 56
TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025 57
TABLE 3 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025 57
5.2.1.2 Growing focus on targeted cancer treatment 58
5.2.1.3 Increasing aging population and subsequent rise in prevalence of chronic diseases 58
5.2.1.4 Increasing penetration of molecular cytogenetics in clinical pathological testing 59
5.2.2 MARKET RESTRAINTS 60
5.2.2.1 High cost of advanced instruments 60
5.2.2.2 Unfavorable reimbursement scenario 60
5.2.3 MARKET OPPORTUNITIES 61
5.2.3.1 Untapped emerging markets 61
5.2.4 MARKET CHALLENGES 61
5.2.4.1 Transition from FISH to array-based techniques 61
5.3 PRICING ANALYSIS 62
5.3.1 PRICING MODEL ANALYSIS 62
TABLE 4 INDICATIVE PRICING ANALYSIS FOR MOLECULAR CYTOGENETIC PRODUCTS 62
5.3.2 AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER 62
TABLE 5 AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS 62
5.4 PATENT ANALYSIS 63
5.4.1 PATENT ANALYSIS OF MOLECULAR CYTOGENETIC PRODUCTS (JANUARY 2013–DECEMBER 2022) 63
5.4.2 MOLECULAR CYTOGENETICS MARKET: LIST OF MAJOR PATENTS 64
5.5 TRADE ANALYSIS 65
5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 65
5.5.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million) 65
5.5.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million) 65
5.6 VALUE CHAIN ANALYSIS 66
FIGURE 20 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 66
5.7 SUPPLY CHAIN ANALYSIS 67
FIGURE 21 MOLECULAR CYTOGENETICS MARKET: SUPPLY CHAIN ANALYSIS 67
5.8 ECOSYSTEM ANALYSIS 68
FIGURE 22 MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ANALYSIS 68
5.8.1 ROLE IN ECOSYSTEM 68
TABLE 6 MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ROLE 68
5.9 PORTER’S FIVE FORCES ANALYSIS 69
TABLE 7 MOLECULAR CYTOGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 69
5.9.1 THREAT OF NEW ENTRANTS 69
5.9.2 THREAT OF SUBSTITUTES 69
5.9.3 BARGAINING POWER OF BUYERS 69
5.9.4 BARGAINING POWER OF SUPPLIERS 69
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.10 PESTLE ANALYSIS 70
5.11 REGULATORY ANALYSIS 71
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 11 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.11.1 NORTH AMERICA 72
5.11.1.1 US 72
5.11.1.2 Canada 72
5.11.2 EUROPE 73
TABLE 12 EUROPE: CLASSIFICATION OF DEVICES 73
5.11.3 ASIA PACIFIC 74
5.11.3.1 China 74
5.11.3.2 Japan 74
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 74
5.11.3.3 India 74
5.11.4 LATIN AMERICA 75
5.11.4.1 Brazil 75
5.11.4.2 Mexico 75
5.11.5 MIDDLE EAST 75
5.11.6 AFRICA 76
5.12 KEY CONFERENCES & EVENTS IN 2022–2023 76
TABLE 14 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 76
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
FIGURE 23 REVENUE SHIFT AND REVENUE POCKETS FOR MOLECULAR CYTOGENETICS MARKET 77
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 78
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 78
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS 78
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS (%) 78
5.14.2 BUYING CRITERIA 79
FIGURE 25 KEY BUYING CRITERIA FOR MOLECULAR CYTOGENETIC END USERS 79
TABLE 16 KEY BUYING CRITERIA 79
5.15 CASE STUDY ANALYSIS 79
5.15.1 CASE STUDY: CYTOGENETIC ANALYSIS OF WISKOTT-ALDRICH SYNDROME 79
6 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE 81
6.1 INTRODUCTION 82
TABLE 17 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 82
6.2 KITS & REAGENTS 83
TABLE 18 MOLECULAR CYTOGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 83
TABLE 19 MOLECULAR CYTOGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 84
6.2.1 TESTING KITS 84
6.2.1.1 Growing advancements in test kits to support market growth 84
TABLE 20 MOLECULAR CYTOGENETICS MARKET FOR TESTING KITS, BY REGION, 2021–2028 (USD MILLION) 85
6.2.2 PROBES 85
6.2.2.1 Increased usage of probes for in situ hybridization to propel market 85
TABLE 21 MOLECULAR CYTOGENETICS MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION) 86
6.2.3 FLUORESCENT AFFINITY REAGENTS 86
6.2.3.1 Development of novel cytogenetic reagents to drive growth 86
TABLE 22 MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENT AFFINITY REAGENTS, BY REGION, 2021–2028 (USD MILLION) 87
6.2.4 OTHER KITS & REAGENTS 87
TABLE 23 MOLECULAR CYTOGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 87
6.3 INSTRUMENTS 88
6.3.1 INCREASING USAGE OF INSTRUMENTS IN DRUG DISCOVERY TO DRIVE MARKET 88
TABLE 24 MOLECULAR CYTOGENETICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 88
6.4 CONSUMABLES 89
6.4.1 INCREASING AWARENESS ABOUT EARLY-STAGE CANCER DIAGNOSIS TO DRIVE MARKET 89
TABLE 25 MOLECULAR CYTOGENETICS MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 89
6.5 SOFTWARE & SERVICES 89
6.5.1 GROWING NEED FOR SOFTWARE SOLUTIONS FOR HIGH CONTENT SCREENING TO PROPEL MARKET 89
TABLE 26 MOLECULAR CYTOGENETICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 90
7 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE 91
7.1 INTRODUCTION 92
TABLE 27 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 92
7.2 COMPARATIVE GENOMIC HYBRIDIZATION 92
TABLE 28 MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY TYPE, 2021–2028 (USD MILLION) 93
TABLE 29 MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 93
7.2.1 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION 94
7.2.1.1 Rising prevalence of human genetic disorders to support market growth 94
TABLE 30 MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 94
7.2.2 STANDARD COMPARATIVE GENOMIC HYBRIDIZATION 95
7.2.2.1 Increased focus on cancer research to drive growth 95
TABLE 31 MOLECULAR CYTOGENETICS MARKET FOR STANDARD COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 95
7.3 FLUORESCENCE IN SITU HYBRIDIZATION 95
7.3.1 ADVANCES IN FLUORESCENCE MICROSCOPY TO BOOST MARKET 95
TABLE 32 MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 96
7.4 CHROMOGENIC IN SITU HYBRIDIZATION 96
7.4.1 COST-EFFECTIVENESS OVER FLUORESCENT IN SITU HYBRIDIZATION FISH TO SUPPORT ADOPTION 96
TABLE 33 MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 97
7.5 OTHER TECHNIQUES 97
TABLE 34 MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION) 98
8 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION 99
8.1 INTRODUCTION 100
TABLE 35 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
8.2 GENETIC DISORDERS 100
8.2.1 INCREASING EFFORTS TO STUDY GENETIC ACTIVITIES TO SUPPORT MARKET GROWTH 100
TABLE 36 MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 101
8.3 CANCER 101
8.3.1 STRATEGIC DEVELOPMENTS IN CANCER RESEARCH TO DRIVE MARKET GROWTH 101
TABLE 37 MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 102
8.4 PERSONALIZED MEDICINE 102
8.4.1 INITIATIVES BY MARKET PLAYERS FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 102
TABLE 38 MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION) 103
8.5 OTHER APPLICATIONS 103
TABLE 39 MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 104
9 MOLECULAR CYTOGENETICS MARKET, BY END USER 105
9.1 INTRODUCTION 106
TABLE 40 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
9.2 CLINICAL & RESEARCH LABORATORIES 106
9.2.1 GROWING RESEARCH INTENSITY TO DRIVE USAGE OF MOLECULAR CYTOGENETIC PRODUCTS 106
TABLE 41 MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 107
9.3 ACADEMIC RESEARCH INSTITUTES 107
9.3.1 INCREASE IN RESEARCH FUNDING FOR LIFE SCIENCE PROJECTS TO DRIVE MARKET 107
TABLE 42 MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 108
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 108
9.4.1 GROWING IMPORTANCE OF MOLECULAR CYTOGENETICS FOR DRUG DISCOVERY TO SUPPORT MARKET GROWTH 108
TABLE 43 MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 109
9.5 OTHER END USERS 109
TABLE 44 MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 110
10 MOLECULAR CYTOGENETICS MARKET, BY REGION 111
10.1 INTRODUCTION 112
TABLE 45 MOLECULAR CYTOGENETICS MARKET, BY REGION, 2021–2028 (USD MILLION) 112
10.2 NORTH AMERICA 112
TABLE 46 LIST OF RELATED CONFERENCES HELD IN NORTH AMERICA 113
FIGURE 26 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET SNAPSHOT 113
TABLE 47 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 48 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 114
TABLE 49 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 115
TABLE 50 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 51 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
10.2.1 NORTH AMERICA: RECESSION IMPACT 116
10.2.2 US 117
10.2.2.1 US to dominate North American molecular cytogenetics market 117
TABLE 52 US: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 118
TABLE 53 US: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 118
TABLE 54 US: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 55 US: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.2.3 CANADA 119
10.2.3.1 Rising prevalence of cancer to drive market 119
TABLE 56 CANADA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
TABLE 57 CANADA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 120
TABLE 58 CANADA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 59 CANADA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.3 EUROPE 122
FIGURE 27 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 122
TABLE 60 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 61 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 123
TABLE 62 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 124
TABLE 63 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 64 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 125
10.3.1 EUROPE: RECESSION IMPACT 125
10.3.2 GERMANY 125
10.3.2.1 Increasing healthcare expenditure with favorable government policies to propel market 125
TABLE 65 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 126
TABLE 66 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 127
TABLE 67 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 127
TABLE 68 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 128
10.3.3 UK 128
10.3.3.1 Availability of government funding and strategic collaborations to boost market 128
TABLE 69 UK: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 129
TABLE 70 UK: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 129
TABLE 71 UK: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 130
TABLE 72 UK: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.3.4 FRANCE 130
10.3.4.1 Increasing government investments to boost growth of French molecular cytogenetics market 130
TABLE 73 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 131
TABLE 74 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 132
TABLE 75 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 132
TABLE 76 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 133
10.3.5 ITALY 133
10.3.5.1 Favorable funding scenario to drive adoption of molecular cytogenetics 133
TABLE 77 ITALY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 78 ITALY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 134
TABLE 79 ITALY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 135
TABLE 80 ITALY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 135
10.3.6 SPAIN 135
10.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players 135
TABLE 81 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 136
TABLE 82 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 136
TABLE 83 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 84 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 137
10.3.7 REST OF EUROPE 138
TABLE 85 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 138
TABLE 86 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 139
TABLE 87 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 139
TABLE 88 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 140
10.4 ASIA PACIFIC 140
FIGURE 28 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET SNAPSHOT 141
TABLE 89 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 90 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142
TABLE 91 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 143
TABLE 92 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 93 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.4.1 ASIA PACIFIC: RECESSION IMPACT 144
10.4.2 CHINA 144
10.4.2.1 Increased cancer cases to propel market 144
TABLE 94 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 145
TABLE 95 CHINA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 96 CHINA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 146
TABLE 97 CHINA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 98 CHINA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 147
10.4.3 JAPAN 147
10.4.3.1 Universal health reimbursement policy to support market growth 147
TABLE 99 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 148
TABLE 100 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 148
TABLE 101 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 149
TABLE 102 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 149
10.4.4 INDIA 149
10.4.4.1 Increasing adoption of technology to support market growth 149
TABLE 103 INDIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 150
TABLE 104 INDIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 151
TABLE 105 INDIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 151
TABLE 106 INDIA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 152
10.4.5 REST OF ASIA PACIFIC 152
TABLE 107 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 153
TABLE 108 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 153
TABLE 109 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
TABLE 110 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 154
10.5 LATIN AMERICA 155
10.5.1 EXPANSIONS OF KEY PLAYERS IN LATIN AMERICAN REGION TO BOOST MARKET 155
TABLE 111 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 155
TABLE 112 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 156
TABLE 113 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 156
TABLE 114 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 157
10.5.2 LATIN AMERICA: RECESSION IMPACT 157
10.6 MIDDLE EAST & AFRICA 157
10.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENT TO PROPEL MARKET 157
TABLE 115 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 158
TABLE 116 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 158
TABLE 117 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 118 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 159
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 159
11 COMPETITIVE LANDSCAPE 160
11.1 OVERVIEW 160
11.2 STRATEGIES OF KEY PLAYERS 160
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR CYTOGENETICS MARKET 160
TABLE 119 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR CYTOGENETICS MANUFACTURING COMPANIES 160
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 162
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS MARKET 162
11.4 MARKET SHARE ANALYSIS 163
FIGURE 30 MOLECULAR CYTOGENETICS MARKET SHARE, BY KEY PLAYER, 2022 163
TABLE 120 MOLECULAR CYTOGENETICS MARKET: DEGREE OF COMPETITION 164
11.5 COMPANY EVALUATION MATRIX 165
11.5.1 LIST OF EVALUATED VENDORS 165
11.5.2 STARS 165
11.5.3 EMERGING LEADERS 165
11.5.4 PERVASIVE PLAYERS 165
11.5.5 PARTICIPANTS 165
FIGURE 31 MOLECULAR CYTOGENETICS MARKET: COMPANY EVALUATION MATRIX, 2022 166
11.5.6 COMPANY FOOTPRINT ANALYSIS 167
TABLE 121 COMPANY TYPE FOOTPRINT 167
TABLE 122 COMPANY REGIONAL FOOTPRINT 167
11.6 STARTUP/SME EVALUATION MATRIX 168
11.6.1 PROGRESSIVE COMPANIES 168
11.6.2 RESPONSIVE COMPANIES 168
11.6.3 DYNAMIC COMPANIES 168
11.6.4 STARTING BLOCKS 168
FIGURE 32 MOLECULAR CYTOGENETICS MARKET: STARTUP/SME EVALUATION MATRIX, 2022 169
11.6.5 COMPETITIVE BENCHMARKING 170
FIGURE 33 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS MARKET 170
TABLE 123 MOLECULAR CYTOGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 170
11.7 COMPETITIVE SCENARIO & TRENDS 171
11.7.1 PRODUCT LAUNCHES 171
TABLE 124 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–NOVEMBER 2023) 171
11.7.2 DEALS 171
TABLE 125 KEY DEALS (JANUARY 2020–NOVEMBER 2023) 171
11.7.3 OTHER DEVELOPMENTS 173
TABLE 126 OTHER DEVELOPMENTS (JANUARY 2020–NOVEMBER 2023) 173
12 COMPANY PROFILES 174
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS 174
12.1.1 F. HOFFMANN-LA ROCHE LTD. 174
TABLE 127 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 174
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 175
12.1.2 DANAHER CORPORATION 179
TABLE 128 DANAHER CORPORATION: COMPANY OVERVIEW 179
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 180
12.1.3 AGILENT TECHNOLOGIES, INC. 183
TABLE 129 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 183
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 184
12.1.4 ABBOTT LABORATORIES 188
TABLE 130 ABBOTT LABORATORIES: COMPANY OVERVIEW 188
FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 189
12.1.5 THERMO FISHER SCIENTIFIC, INC. 191
TABLE 131 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW 191
FIGURE 38 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 192
12.1.6 ILLUMINA INC. 195
TABLE 132 ILLUMINA INC.: COMPANY OVERVIEW 195
FIGURE 39 ILLUMINA INC.: COMPANY SNAPSHOT (2022) 196
12.1.7 REVVITY 199
TABLE 133 REVVITY: COMPANY OVERVIEW 199
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2022) 200
12.1.8 PACIFIC BIOSCIENCES 202
TABLE 134 PACIFIC BIOSCIENCES: COMPANY OVERVIEW 202
FIGURE 41 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2022) 203
12.1.9 BIO-RAD LABORATORIES, INC. 205
TABLE 135 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 205
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 206
12.1.10 BIO-TECHNE CORPORATION 209
TABLE 136 BIO-TECHNE CORPORATION: COMPANY OVERVIEW 209
FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022) 210
12.1.11 GENEDX 213
TABLE 137 GENEDX: COMPANY OVERVIEW 213
FIGURE 44 GENEDX: COMPANY SNAPSHOT (2022) 214
12.1.12 ONCOCYTE CORPORATION 216
TABLE 138 ONCOCYTE CORPORATION: COMPANY OVERVIEW 216
FIGURE 45 ONCOCYTE CORPORATION: COMPANY SNAPSHOT (2022) 216
12.1.13 BIOVIEW 218
TABLE 139 BIOVIEW: COMPANY OVERVIEW 218
12.2 OTHER PLAYERS 220
12.2.1 OXFORD GENE TECHNOLOGY IP LIMITED (PART OF SYSMEX) 220
12.2.2 APPLIED SPECTRAL IMAGING, INC. 222
12.2.3 CYTOTEST INC. 223
12.2.4 KROMATID, INC. 224
12.2.5 GENIAL GENETIC SOLUTIONS LTD. 225
12.2.6 CYTOGNOMIX, INC. 226
12.2.7 METASYSTEMS 227
12.2.8 SCIGENE 228
12.2.9 BIOMODAL 229
12.2.10 BIOCARE MEDICAL 230
12.2.11 BIODOT 231
12.2.12 ONCODNA 232
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX 233
13.1 DISCUSSION GUIDE 233
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 237
13.3 CUSTOMIZATION OPTIONS 239
13.4 RELATED REPORTS 239
13.5 AUTHOR DETAILS 240

ページTOPに戻る

Table of Contents

Summary

The molecular cytogenetics market is valued at an estimated USD 3.1 billion in 2023 and is projected to reach USD 4.9 billion by 2028, at a CAGR of 9.9% during the forecast period. Increasing in the incidence of chronic diseases like cancer and genetic diseases has lead to the increase in prevalence of the diagnosis of the diseases at earlier stage and diagnosis of the core cause of disease. Urgent and timely treatment is required to manage these patients. The overall increase in the number of research and diagnostic procedures is leading to the increased adoption of molecular cytogenetics in order to ensure theaccurate diagnosis of the diseases. This is driving the overall growth of the market.
“Kits & Reagents segment accounted for the highest growth rate in the molecular cytogenetics market, by product, during the forecast period.”
The molecular cytogenetics market is bifurcated into kits & reagents, instruments, consumables and software & services on the basis of product. The kits & reagents segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as cancers and increasing focus on personalized medicines.
“Comparative genomic hybridization segment accounted for the highest growth rate in the molecular cytogenetics market, by technique, during the forecast period.”
The molecular cytogenetics market is bifurcated into comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques on the basis of technique. The comparative genomic hybridization segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing penetration of molecular cytogenetics in clinical pathology and research.
“Cancer segment accounted for the highest growth rate in the molecular cytogenetics market, by applications, during the forecast period.”
The global molecular cytogenetics market is bifurcated into genetic disorders, cancer, personalized medicine and other applications. The cancer segment is currently witnessing the highest growth rate within the molecular cytogenetics market. The rising geriatric population and rising incidence of cancer due to genetic changes are the major factors driving this segment's growth.
“Clinical & research laboratories segment accounted for the highest CAGR”
Based on end users, the molecular cytogenetics market is segmented into clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users. In 2022, the clinical & research laboratories segment accounted for the highest growth rate. This can be attributed to the increased demand for advanced cytogenetics products for disease diagnosis.
“Asia Pacific: The fastest-growing region molecular cytogenetics market”
The global molecular cytogenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Anticipated growth in this region will primarily focus on China and Japan. Factors such as a growing elderly population, rising cancer prevalence, increased healthcare expenditures, higher per capita income, escalating demand for advanced technology, the expansion of private healthcare sectors across several APAC nations, and the existence of rapidly developing markets are steering the market's growth in this region.
The break-up of the profile of primary participants in the molecular cytogenetics market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in this market are Thermo Fisher Scientific Inc. (US), Illumina Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott Laboratories (US), Agilent Technologies, Inc. (US), Pacific Biosciences (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne Corporation (US), GeneDx (US), Oncocyte Corporation (US), BioView (Israel), Oxford Gene Technology IP, Limited. (UK), Applied Spectral Imaging, Inc. (US), Cyto-Test Inc. (US), KromaTiD, Inc. (US), Genial Genetic Solutions, Ltd. (UK), Cytognomix, Inc. (Canada), MetaSystems (Germany), SciGene (US), Biomodal (UK), Biocare Medical (US), BioDot (US), OncoDNA (Belgium).
Research Coverage:
This research report categorizes the molecular cytogenetics market by product (kits & reagents, instruments, consumables and software & services), technique (comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques), application (genetic disorders, cancer, personalized medicine and other applications), end user (clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities and challenges, influencing the growth of the molecular cytogenetics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the molecular cytogenetics market. Competitive analysis of upcoming startups in the molecular cytogenetics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular cytogenetics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments, unfavorable reimbursement scenario), opportunities (untapped emerging markets in Asia) and challenges (transition from FISH to array-based techniques) influencing the growth of the molecular cytogenetics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular cytogenetics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the molecular cytogenetics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), among others in the molecular cytogenetics market strategies.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?